Showing results (4211-4220 of 5,702) with videos related to

Sort By:
Pageof 571
The Oncologist|July 17, 2026
Feasibility of decentralized cervical cancer survivorship care at district hospitals in Rwanda: a multi-site pilot implementation studyFidel Rubagumya, Vincent Kwizera, Isabelle Mutetiwabo, et al.
The Oncologist|August 28, 2026
Use of real-world evidence in the U.S. Food and Drug Administration and the European Medicines Agency approvals of oncology products supported by single-arm trials (2022-2025)Le Su, Lei Chen, Ronac Mamtani, et al.
The Oncologist|September 1, 2026
Real-world Experience with Ipilimumab in Combination with Nivolumab in Advanced Sarcoma: A Retrospective Analysis Including Ultra-Rare SarcomasBenjamin Snyder, Casey Wendorff, Korbin Davis, et al.
The Oncologist|July 24, 2026
SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1m advanced breast cancer during first-line endocrine-based therapyAdam Brufsky, Yeon Hee Park, François-Clément Bidard, et al.
The Oncologist|August 3, 2026
A Silent Gap: Underrepresentation of Latin American Patients in Pivotal Genitourinary and Skin Cancer TrialsErika Adriana Martinez-Castaneda, Ava Isabella De Pellegrin Overgaard, Jean Henri Maselli-Schoueri, et al.
The Oncologist|August 22, 2026
Novel Genomic Score Predicts Survival with Immune checkpoint inhibition in Neuroendocrine NeoplasmsTanvi Brar, Charles Olowookere, Dat Le, et al.
The Oncologist|August 19, 2026
Declining rural oncologist supply in the United States: A workforce analysis from 2014 to 2025David X Zheng
The Oncologist|August 17, 2026
Phase II Study of Olaparib Plus Durvalumab in EGFR-Mutant NSCLC Transformed to Small Cell Lung CancerChirayu Mohindroo, Nobuyuki Takahashi, Samantha Nichols, et al.
The Oncologist|August 17, 2026
Identification of key symptoms impacting HRQOL in advanced renal cell carcinoma: nivolumab plus cabozantinib versus sunitinib in CheckMate 9ERCristiane Bergerot, Shengsheng Yu, Min Yang, et al.
The Oncologist|September 25, 2026
Overall survival in oncology phase III trials: an individual patient level meta-analysis (OPTIMA)Alexander D Sherry, Noah Meimoun, Avital M Miller, et al.
Pageof 571